

Screening Libraries

Proteins

Inhibitors

Product Data Sheet

TRAIL/TNFSF10 Protein, Mouse (His, Solution)

Cat. No.: HY-P7089

Synonyms: rMuTRAIL/TNFSF10; TNF-related apoptosis-inducing ligand; Tumor necrosis factor ligand

superfamily member 10

Mouse Species: Source: E. coli

Accession: P50592 (P118-N291)

Gene ID: 22035

Molecular Weight: Approximately 22.0 kDa

PROPERTIES

AA Sequer	ıce
-----------	-----

PRGGRPQKVA AHITGITRRS NSALIPISKD GKTLGQKIES WESSRKGHSF LNHVLFRNGE LVIEQEGLYY IYSQTYFRFQ EAEDASKMVS KDKVRTKQLV QYIYKYTSYP DPIVLMKSAR NSCWSRDAEY GLYSIYQGGL FELKKNDRIF VSVTNEHLMD

LDQEASFFGA FLIN

Appearance

Solution.

Formulation

Supplied as a 0.22 μm filtered solution of PBS, 25% glycerol, pH7.4.

Endotoxin Level

<1 EU/µg, determined by LAL method.

Reconsititution

N/A

Storage & Stability

Stored at -80°C for 1 year. It is stable at -20°C for 3 months after opening. It is recommended to freeze aliquots at -80°C for extended storage. Avoid repeated freeze-thaw cycles.

Shipping

Shipping with dry ice.

DESCRIPTION

Background

TRAIL Protein (TNFSF10), a member of the TNF superfamily, is a type II transmembrane protein. TRAIL Protein is expressed in various tissues, especially in the spleen, lung, and prostate. TRAIL protein is mainly expressed on surface of immune cells, such as cytotoxic T cells and natural killer (NK) cell. TRAIL proteins on NK and T cells is critical for controlling virus infections and tumor immune surveillance^{[1][2]}.

Mouse TRAIL consists of cytoplasmic domain (M1-R17), helical domain (M18-T38), and extracellular domain (Y39-N291). Mouse TRAIL Protein shares < 70% common aa identity with human. Mouse TRAIL Protein shares 86.94% common aa identity with rat.

TRAIL Protein mainly interacts with two agonistic TRAIL receptors (TRAIL-R1 and TRAIL-R2) and induces apoptosis in tumor

Page 1 of 2

or infected cells. TRAIL Protein also binds with DR4, DR5, and OPG. When binding to DR4 or DR5, TRAIL Protein can recruit FADD and further recruit and activates caspase-8. Besides, TRAIL may also trigger nonapoptotic signaling through activating pro-inflammatory pathways, such as NF-kB, PI3K/Akt, and MAPK pathway^{[1][2]}.

TRAIL induces apoptosis of tumor cells in a p53 independent manner. TRAIL-based therapies has high anti-tumor potential [3]

REFERENCES

- [1]. Cardoso Alves L, et al. The multifaceted role of TRAIL signaling in cancer and immunity. FEBS J. 2021 Oct;288(19):5530-5554.
- [2]. Zhong HH, et al. TRAIL-based gene delivery and therapeutic strategies. Acta Pharmacol Sin. 2019 Nov;40(11):1373-1385.
- [3]. Snajdauf M, et al. The TRAIL in the Treatment of Human Cancer: An Update on Clinical Trials. Front Mol Biosci. 2021 Mar 10;8:628332.
- [4]. Weckmann M, et al. Critical link between TRAIL and CCL20 for the activation of TH2 cells and the expression of allergic airway disease. Nat Med. 2007 Nov;13(11):1308-15.
- [5]. Pitti RM, et al. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem. 1996 May 31;271(22):12687-90.
- [6]. Wang S, et al. TRAIL and apoptosis induction by TNF-family death receptors. Oncogene. 2003 Nov 24;22(53):8628-33.
- [7]. Almasan A, et al. Apo2L/TRAIL: apoptosis signaling, biology, and potential for cancer therapy. Cytokine Growth Factor Rev. 2003 Jun-Aug;14(3-4):337-48.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

 $\hbox{E-mail: } tech@MedChemExpress.com$

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA